Success Metrics

Clinical Success Rate
75.0%

Based on 6 completed trials

Completion Rate
75%(6/8)
Active Trials
0(0%)
Results Posted
67%(4 trials)
Terminated
2(22%)

Phase Distribution

Ph phase_1
2
22%
Ph phase_2
1
11%
Ph phase_3
5
56%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
5(62.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

6 of 8 finished

Non-Completion Rate

25.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

9

all time

Status Distribution
Completed(6)
Terminated(2)
Other(1)

Detailed Status

Completed6
Terminated2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 21 (12.5%)
Phase 35 (62.5%)

Trials by Status

completed667%
unknown111%
terminated222%

Recent Activity

0 active trials
Showing 5 of 9
terminatedphase_3

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

NCT06011577
terminatedphase_3

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NCT04855747
completedphase_3

Safety of REL-1017 for Major Depressive Disorder

NCT04855760
completedphase_3

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

NCT04688164
unknown

Individual Patient Esmethadone (REL-1017) Expanded Access Program

NCT06009003
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06011577Phase 3

Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD

Terminated
NCT04855747Phase 3

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

Terminated
NCT04855760Phase 3

Safety of REL-1017 for Major Depressive Disorder

Completed
NCT04688164Phase 3

A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)

Completed
NCT06009003

Individual Patient Esmethadone (REL-1017) Expanded Access Program

Unknown
NCT05081167Phase 3

A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD)

Completed
NCT03051256Phase 2

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD

Completed
NCT03637361Phase 1

Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone)

Completed
NCT03638869Phase 1

Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone)

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9